ADRENALIN (epinephrine in sodium chloride) by Pfizer is adrenergic alpha-agonists [moa]. First approved in 2023.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
ADRENALIN is an intravenous epinephrine solution in sodium chloride approved by the FDA in April 2023. It functions as an alpha-adrenergic agonist, stimulating adrenergic receptors to produce sympathomimetic effects. The product is indicated for acute hemodynamic support in critical care settings where rapid cardiovascular intervention is required.
Early-stage peak revenue generation with modest Part D penetration suggests focused commercial infrastructure for a critical care IV product with limited outpatient presence.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis
Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection
Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline
Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext
Worked on ADRENALIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ADRENALIN offers career stability through a monopoly-positioned critical care product with extended patent protection until 2039 and zero competitive pressure. This role emphasizes hospital/ICU channel expertise, relationship management with critical care networks, and medical affairs support to intensivists rather than broader primary care commercial skills.